BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 36006861)

  • 1. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
    Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
    J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
    Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
    Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
    Alabi SB; Crews CM
    J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing targeted protein degradation for metabolic diseases therapy.
    Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
    Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
    Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
    Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
    Li J; Chen X; Lu A; Liang C
    Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging degrader technologies engaging lysosomal pathways.
    Ding Y; Xing D; Fei Y; Lu B
    Chem Soc Rev; 2022 Oct; 51(21):8832-8876. PubMed ID: 36218065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
    Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
    Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifaceted targeted protein degradation systems for different cellular compartments.
    Zorca CE; Fallahi A; Luo S; Eldeeb MA
    Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress of small molecules for targeted protein degradation: PROTACs and other technologies.
    Zhao HY; Xin M; Zhang SQ
    Drug Dev Res; 2023 Apr; 84(2):337-394. PubMed ID: 36606428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders.
    Tomoshige S; Ishikawa M
    Angew Chem Int Ed Engl; 2021 Feb; 60(7):3346-3354. PubMed ID: 32410219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.
    Inuzuka H; Liu J; Wei W; Rezaeian AH
    Acta Mater Med; 2022; 1(1):24-41. PubMed ID: 35237768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances of targeted protein degradation technology and its applications in diseases therapy].
    Chen S; Yang H; Jiang J; Yu S; Li T; Ge S
    Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3915-3932. PubMed ID: 34841795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
    Cassidy K; Zhao H
    Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted protein degradation: A promise for undruggable proteins.
    Samarasinghe KTG; Crews CM
    Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.
    Ruffilli C; Roth S; Rodrigo M; Boyd H; Zelcer N; Moreau K
    ACS Pharmacol Transl Sci; 2022 Oct; 5(10):849-858. PubMed ID: 36268122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research.
    Li X; Liu Q; Xie X; Peng C; Pang Q; Liu B; Han B
    J Med Chem; 2023 Feb; 66(3):1700-1711. PubMed ID: 36716420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major Advances in Emerging Degrader Technologies.
    Luo H; Wu L; He Y; Qin C; Tang X
    Front Cell Dev Biol; 2022; 10():921958. PubMed ID: 35813205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.